Why It Might Be Good for the Pharmaceutical Industry in the Long Run
A Different Take on Business Acumen and Market Dynamics
The headlines flashed like lightning:
“Trump Says He Will Sign Executive Order Aimed at Lowering Drug Prices”
“U.S. Drug Prices Will Be Pegged to International Rates”
And predictably, the immediate reaction across the pharmaceutical industry and markets was panic. The initial narrative was straightforward from a business acumen perspective: this move would slash revenues, limit pricing flexibility, and discourage investment in research and development (R&D).
But at Advantexe, where we develop business acumen simulations for global pharmaceutical companies, the reaction was different. Our team started texting immediately, not with fear, but with questions. How do we help clients navigate this curveball? How do we reframe the conversation?
We’ve been simulating this very scenario for months, introducing it as a “wobbler” in our learning experiences. And here’s the surprising conclusion we’ve come to:
Read More >